What You Should Know:
– Avenda Health, a pioneer in AI-powered prostate cancer care, announced today that the Centers for Medicare & Medicaid Services (CMS) has assigned a national payment rate for its prostate cancer mapping technology, Unfold AI.
– This significant development, alongside the establishment of a new Category III code by the American Medical Association (AMA), paves the way for broader adoption of Unfold AI and improved prostate cancer diagnosis and treatment.
Unfold AI: A Game-Changer in Prostate Cancer Detection
Using a patient’s standard of care data (MRI, fusion biopsy, pathology and PSA) and artificial intelligence, Unfold AI generates a heatmap or Cancer Estimation Map (CEM) that visualizes where the cancer is in 3D, significantly outperforming MRI’s ability to identify exactly where all the cancer resides in the prostate. The new AMA Category III code, 0898T, enables healthcare providers to bill for services related to using Unfold AI, including the creation of these maps.
Medicare Reimbursement
Medicare’s decision to assign a national payment rate for Unfold AI underscores the technology’s growing recognition within the healthcare industry. This move will facilitate wider access to the technology for patients and providers. While Medicare reimbursement is determined by the Hospital Outpatient Prospective Payment System (OPPS), reimbursement for physician services and commercial payers will be based on individual contracts and regional variations.
Clinical Validation and Improved Patient Outcomes
A recent study published in The Journal of Urology highlighted Unfold AI’s impressive accuracy in identifying the extent of prostate cancer. The technology demonstrated a remarkable 84% accuracy rate, outperforming traditional methods by a factor of 45. This breakthrough has the potential to revolutionize prostate cancer diagnosis and treatment, leading to more targeted therapies and reduced side effects.
Impact
By combining advanced AI with clinical expertise, Unfold AI offers a promising solution for improving patient outcomes and enhancing the overall standard of care. As reimbursement and adoption continue to expand, the technology has the potential to transform the landscape of prostate cancer diagnosis and treatment.
“Receiving the new CPT code and national payment rate for Unfold AI is an important development in making advanced personalized prostate cancer care accessible to more patients,” said Avenda Health COO Brit Berry-Pusey, PhD. “This recognition by the AMA and CMS validates the transformative potential of our technology in improving diagnostic accuracy and patient outcomes.”
